Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | Director · President & CBO | January 09, 2023 | January 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LISATA THERAPEUTICS, INC.
Report date January 09, 2023 · Filed January 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,642 |
Last balance in matching sequence
After 2023-01-09 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-01-09 · Grant · Acquired 24,000 · Balance 24,000 F1: Represents 24,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2: Includes 18,000 unvested restricted stock. Row 2 · 2023-01-09 · Tax withholding · Disposed 3,358 · Balance 20,642 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 18,000 unvested restricted stock. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2033-01-09 | Direct | 12,000 |
Reported balance
After 2023-01-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-09 · Grant · Acquired 12,000 · Balance 12,000 F4: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 24,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
F2: Includes 18,000 unvested restricted stock.
F3: Shares withheld as payment of a tax liability on vesting of restricted stock.
F4: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2023 Filed Jan 11, 2023 21:10 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Options (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001943584-23-000002 · wf-form4_167347139126847.xml · derivative · entry 3 Slack David W. · CIK 0001943584 · Director · President & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-01-09 F4 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:10 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 3,358 | $3.00 | $10,074.00 |
DisclosureSEC source: 0001943584-23-000002 · wf-form4_167347139126847.xml · nonDerivative · entry 2 Slack David W. · CIK 0001943584 · Director · President & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,642 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 18,000 unvested restricted stock. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:10 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001943584-23-000002 · wf-form4_167347139126847.xml · nonDerivative · entry 1 Slack David W. · CIK 0001943584 · Director · President & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 F1 · shares: Represents 24,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 18,000 unvested restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.